Results 211 to 220 of about 30,616 (272)

Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections and associated risk factors among pregnant women and key populations in Kenya: A multi-centre cross-sectional study. [PDF]

PLOS Glob Public Health
Ngugi C, Nyaoke BA, Kingwara L, Akinyi P, Mmbone M, Egondi TW, Nyangweso GM, Broadhurst H, Kornmann G, Mathur R, Bettiol E.   +10 more
europepmc   +1 more source

Effects of improved partner notification on the transmission of HIV and <i>N. gonorrhoea</i> among men who have sex with men: a modelling study. [PDF]

Sex Transm Infect
Reitsema M, Wallinga J, van Benthem BHB, Op de Coul ELM, Van Sighem A, Schim van der Loeff M, Xiridou M.   +6 more
europepmc   +1 more source

Prevalence and Determinants of Common Sexually Transmitted Infections Among Women Presenting with Vaginal Discharge at a Tertiary Care Hospital in Eritrea. [PDF]

Int J Womens Health
Berhane A, Tesfai B, Frezgi O, Hussein KF, Kibreab F.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study

Lancet, The
BACKGROUND Gepotidacin, a first-in-class, bactericidal, triazaacenaphthylene antibacterial that inhibits bacterial DNA replication, was shown to be efficacious and well tolerated in the treatment of uncomplicated urinary tract infections.
Jonathan D C Ross, Janet Wilson, Kimberly A. Workowski, Stephanie N Taylor, D. Lewis, Sally Gatsi, W. Flight, N. Scangarella-Oman, C. Jakielaszek, Dan Lythgoe, Marcy Powell, Salim Janmohamed, Judith Absalon, C. Perry   +13 more
exaly   +2 more sources

Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study

Lancet, The, 2017
Helen A Petousis-Harris, Janine Paynter, Peter J W Saxton   +2 more
exaly   +2 more sources

4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post program implementation.

Journal of Infection, 2023
OBJECTIVES To evaluate persistence of vaccine effectiveness (VE) and vaccine impact (VI) on invasive meningococcal B (MenB) disease and gonorrhoea at three years after implementation of a state funded 4CMenB program for infants, children, adolescents and
Bing Wang, L. Giles, P. Andraweera, M. McMillan, S. Almond, R. Beazley, Janine Mitchell, Michele Ahoure, Emma Denehy, L. Flood, H. Marshall   +10 more
semanticscholar   +1 more source

Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.

Lancet. Infectious Diseases (Print), 2022
BACKGROUND A programme of vaccination with the four-component serogroup B meningococcal (4CMenB) vaccine was introduced in South Australia for infants and children aged 0-3 years on Oct 1, 2018, and for senior school students in school years 10 and 11 ...
Bing Wang, L. Giles, P. Andraweera, M. McMillan, S. Almond, R. Beazley, Janine Mitchell, Noel Lally, Michele Ahoure, Emma Denehy, A. Koehler, L. Flood, H. Marshall   +12 more
semanticscholar   +1 more source

Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial.

Lancet. Infectious Diseases (Print), 2022
BACKGROUND Neisseria gonorrhoeae causes gonorrhoea, a common sexually transmitted infection. Emerging strains resistant to first-line ceftriaxone threaten N gonorrhoeae management. Hence, alternative treatments are needed.
H. D. de Vries, M. D. de Laat, V. Jongen, T. Heijman, Carolien M. Wind, A. Boyd, J. de Korne-Elenbaas, A. V. van Dam, M. F. Schim van der Loeff   +8 more
semanticscholar   +1 more source